

EXPERT CONSENSUS DECISION PATHWAY

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force

**Periprocedural
 Management of
 Anticoagulation
 Writing
 Committee**

John U. Doherty, MD, FACC, *Chair*
 Ty J. Gluckman, MD, FACC
 William J. Hucker, MD, PhD
 James L. Januzzi, Jr, MD, FACC

Thomas L. Ortel, MD, PhD
 Sherry J. Saxonhouse, MD, FACC
 Sarah A. Spinler, PHARM, AACC

**Task Force on
 Clinical Expert
 Consensus
 Documents**

James L. Januzzi, Jr, MD, FACC, *Chair*
 Luis C. Afonso, MBBS, FACC
 Brendan Everett, MD, FACC
 Jonathan Halperin, MD, FACC
 Adrian Hernandez, MD, FACC
 William Hucker, MD
 Hani Jneid, MD, FACC
 Dharam Kumbhani, MD, SM, FACC

Eva M. Lonn, MD, FACC
 Joseph Marine, MD, FACC
 James K. Min, MD, FACC
 Pamela B. Morris, MD, FACC
 Robert Piana, MD, FACC
 John Puskas, MD, FACC
 Karol E. Watson, MD, FACC
 Barbara S. Wiggins, PHARM, AACC

This document was approved by the American College of Cardiology Board of Trustees in November 2016.

The American College of Cardiology Foundation requests that this document be cited as follows: Doherty JU, Gluckman TJ, Hucker WJ, Januzzi Jr. JL, Ortel TL, Saxonhouse SJ, Spinler SA. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. *J Am Coll Cardiol* 2017;XX:XXX-XX.

Copies: This document is available on the World Wide Web site of the American College of Cardiology (www.acc.org). For copies of this document, please contact Elsevier Reprint Department, fax (212) 633-3820, or e-mail reprints@elsevier.com.

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology. Requests may be completed online via the Elsevier site (<http://www.elsevier.com/about/policies/author-agreement/obtaining-permission>).

TABLE OF CONTENTS

ABSTRACT	■	5.9. Postprocedural Reinitiation of Anticoagulant Therapy	■
PREFACE	■	5.10. Restarting VKA Therapy	■
1. INTRODUCTION	■	5.11. Indications for Postprocedural Parenteral Bridging and Unique Postprocedural Indications	■
2. METHODS	■	5.12. Use of Parenteral Anticoagulation Postprocedure in Patients With Moderate or High Thrombotic Risk: Clinical Factors and Monitoring	■
3. ASSUMPTIONS AND DEFINITIONS	■	5.13. Reinitiation of DOAC Therapy	■
3.1. General Clinical Assumptions	■	5.13.1. Dabigatran	■
3.2. Definitions	■	5.13.2. Rivaroxaban	■
4. PATHWAY SUMMARY GRAPHIC	■	5.13.3. Apixaban	■
Figure 1. PMAC Pathway Decision Algorithm Summary	■	5.13.4. Edoxaban	■
5. DESCRIPTION AND RATIONALE	■	5.14. Scenarios Requiring Special Consideration for DOAC Reinitiation	■
5.1. Periprocedural Interruption of Anticoagulant Therapy	■	5.14.1. Prolonged Period of Inability to Take Oral Medications Following a Procedure in Patients Taking a DOAC	■
5.2. Assessing Procedural Bleed Risk	■	5.14.2. Postprocedural Venous Thromboembolism Prophylaxis	■
5.3. Assessing Patient-Related Bleed Risk	■	5.14.3. Neuraxial Anesthesia	■
Table 1. Patient Bleed Risk Factors	■	5.14.4. Restarting Anticoagulation After a Procedure With an Unknown Bleed Risk	■
5.4. Periprocedural DOAC use with neuraxial procedures	■	5.14.5. Restarting DOAC Therapy Following Cardiac Surgery	■
Figure 2. Detailed Algorithm: Whether to Interrupt, and How to Interrupt for VKAs	■	5.14.6. Bleeding Complications	■
Figure 3. Detailed Algorithm: Whether to Interrupt, and How to Interrupt for DOACs	■	Figure 5. Algorithm: How to Restart Anticoagulation	■
Table 2. Recommended Durations for Withholding DOACs Based on Procedural Bleed Risk and Estimated CrCl When There Are No Increased Patient Bleed Risk Factors	■	6. DISCUSSION AND IMPLICATION OF PATHWAY ...	■
5.5. Parenteral Bridging Anticoagulation in the Periprocedural Setting	■	APPENDIX 1	
5.6. Interruption and Bridging for Patients on DOACs	■	Author Relationships With Industry and Other Entities (Relevant)	■
5.7. Interruption and Bridging for Patients on a VKA	■	APPENDIX 2	
5.7.1. Patients at Low Thrombotic Risk	■	Peer Reviewer Relationships With Industry and Other Entities (Comprehensive)	■
5.7.2. Patients at Moderate Thrombotic Risk	■	APPENDIX 3	
5.7.3. Patients at High Thrombotic Risk	■	Abbreviations	■
5.8. Specific Recommendations Regarding Bridging	■	ABSTRACT	
Figure 4. Algorithm: Whether to Bridge and How to Bridge for DOACs and VKAs	■	Periprocedural management of anticoagulation is a common clinical conundrum that involves a multidisciplinary team, cuts across many specialties, and varies greatly between institutions in the way it is practiced. Nowhere is	

Download English Version:

<https://daneshyari.com/en/article/5607733>

Download Persian Version:

<https://daneshyari.com/article/5607733>

[Daneshyari.com](https://daneshyari.com)